Logo image of CTCX

CARMELL CORP (CTCX) Stock Fundamental Analysis

NASDAQ:CTCX - Nasdaq - US1429221039 - Common Stock

0.455  -0.02 (-3.85%)

After market: 0.456 +0 (+0.22%)

Fundamental Rating

0

CTCX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. CTCX may be in some trouble as it scores bad on both profitability and health. CTCX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CTCX had negative earnings in the past year.
CTCX had a negative operating cash flow in the past year.
CTCX Yearly Net Income VS EBIT VS OCF VS FCFCTCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -1047.37%, CTCX is doing worse than 99.29% of the companies in the same industry.
Industry RankSector Rank
ROA -1047.37%
ROE N/A
ROIC N/A
ROA(3y)-8.43%
ROA(5y)N/A
ROE(3y)-21.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTCX Yearly ROA, ROE, ROICCTCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

CTCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTCX Yearly Profit, Operating, Gross MarginsCTCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

CTCX has more shares outstanding than it did 1 year ago.
CTCX has a worse debt/assets ratio than last year.
CTCX Yearly Shares OutstandingCTCX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
CTCX Yearly Total Debt VS Total AssetsCTCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -52.59, we must say that CTCX is in the distress zone and has some risk of bankruptcy.
CTCX has a Altman-Z score of -52.59. This is amonst the worse of the industry: CTCX underperforms 94.87% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -52.59
ROIC/WACCN/A
WACCN/A
CTCX Yearly LT Debt VS Equity VS FCFCTCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.31 indicates that CTCX may have some problems paying its short term obligations.
CTCX has a Current ratio of 0.31. This is amonst the worse of the industry: CTCX underperforms 95.40% of its industry peers.
A Quick Ratio of 0.29 indicates that CTCX may have some problems paying its short term obligations.
The Quick ratio of CTCX (0.29) is worse than 95.22% of its industry peers.
Industry RankSector Rank
Current Ratio 0.31
Quick Ratio 0.29
CTCX Yearly Current Assets VS Current LiabilitesCTCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CTCX have decreased strongly by -335.72% in the last year.
The Revenue for CTCX has decreased by -99.12% in the past year. This is quite bad
EPS 1Y (TTM)-335.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.4%
Revenue 1Y (TTM)-99.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.45%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTCX Yearly Revenue VS EstimatesCTCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023
CTCX Yearly EPS VS EstimatesCTCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CTCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTCX Price Earnings VS Forward Price EarningsCTCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTCX Per share dataCTCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CTCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARMELL CORP

NASDAQ:CTCX (1/22/2025, 5:20:00 PM)

After market: 0.456 +0 (+0.22%)

0.455

-0.02 (-3.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners17.74%
Inst Owner Change-0.01%
Ins Owners0.6%
Ins Owner Change0.13%
Market Cap9.51M
AnalystsN/A
Price TargetN/A
Short Float %5.97%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 289.71
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0
BVpS-0.19
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1047.37%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.43%
ROA(5y)N/A
ROE(3y)-21.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.31
Quick Ratio 0.29
Altman-Z -52.59
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-335.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.4%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-99.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1727.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1727.38%
OCF growth 3YN/A
OCF growth 5YN/A